-
Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates
•
Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences, Inc. to discover new small molecule drug candidates for immunology and neurology using BridGene’s chemical proteomics platform, IMTAC. The collaboration aims to advance projects through hit finding and early lead development, with Takeda holding exclusive…
-
Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients
•
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved a label extension for Takhzyro (lanadelumab) for subcutaneous administration in adolescents aged 12 and above and adult patients with Hereditary Angioedema (HAE) using a 2 mL pre-filled pen. Drug ProfileTakhzyro is now approved in the…
-
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
•
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period ended December 31, 2024. The company reported revenues of JPY 3.53 trillion ($22.4 billion), representing a 4.5% growth at constant exchange rates (CER). Sales jumped 14.6% year-on-year (YOY) due to the growth period and continuous…
-
Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health
•
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation Center (TCIC) within the Chengdu Hi-Tech Industrial Development Zone. The company has reached an agreement with the district’s management committee to develop the center, which will focus on enhancing digital innovation capabilities in China. TCIC:…
-
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
•
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20 million milestone payment from its Japanese partner Takeda (TYO: 4502; NYSE: TAK), following the achievement of over USD 200 million in sales of Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC). Fruquintinib, a selective oral inhibitor…
-
Takeda’s Entyvio Receives Historic Patent Term Adjustment in China, a First for the Country
•
On August 16, a significant milestone was reached as the China National Intellectual Property Administration (CNIPA) awarded Japanese pharmaceutical company Takeda (NYSE: TAK)’s Entyvio (vedolizumab) a Patent Term Adjustment (PTA) for patent NO. ZL201711310404.0, marking the first case of its kind in China. This decision deviates from the typical Patent…
-
Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach
•
Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly preparing to submit its dengue fever vaccine for regulatory approval in the United States, according to the Nikkei Asian Review. At this juncture, specifics regarding the timing of the filing or the anticipated decision date…
-
Takeda to Slash 1,000 US Jobs as Part of Broader Restructuring Effort
•
Japanese pharmaceutical giant Takeda Pharmaceuticals (TYO: 4502 / NYSE: TAK) has confirmed reports from Nikkei that it is planning to eliminate approximately 1,000 positions in the United States. This move is part of a strategic downsizing that will see the closure of a research facility in San Diego, California, and…
-
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
•
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the first quarter of fiscal year 2024, ending June 30, 2024. The company reported a 2.1% increase in global sales year-on-year, reaching ¥1,208 billion ($7.85 billion) at constant exchange rates. Takeda’s Growth and Launch Product portfolio,…
-
Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge
•
Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking potential partnerships with Chinese biotech firms, according to CEO Christophe Weber in a recent Bloomberg interview. Weber highlighted that despite finalizing two recent agreements with Chinese companies, Takeda is still “very open” to further collaborations,…
-
Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials
•
Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced that its drug candidate soticlestat did not meet the primary endpoints in two Phase III trials. The drug is currently under development for the treatment of two rare forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome—and…
-
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
•
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ: AZN), Bristol Myers Squibb (BMS; NYSE: BMY), and Takeda (NYSE: TAK). These partnerships underscore the biotech company’s commitment to leveraging its integrated AI and wet-lab technologies for the design of conformation- and target-selective antibody candidates.…
-
Takeda Strikes Deal with AC Immune for Global Rights to Alzheimer’s Immunotherapies
•
Takeda Pharmaceutical Company Limited (NYSE: TAK) has entered into an agreement with AC Immune SA (NASDAQ: ACIU), a Switzerland-based developer of advanced immunotherapies, to obtain an exclusive global license for the company’s active immunotherapies that target toxic forms of amyloid beta (Abeta). This strategic partnership positions Takeda at the forefront…
-
HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe
•
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502, NYSE: TAK) has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of fruquintinib for the treatment of adult patients with…
-
Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups
•
Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade association, according to Fierce Pharma. This move makes Takeda the fourth major company to leave BIO since December of the previous year, following the exits of Pfizer and…
-
Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture
•
Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot bank Sumitomo Mitsui to establish a joint venture (JV) aimed at nurturing drug discovery start-ups. The yet-to-be-named JV will leverage the pharmaceutical companies’ expertise to foster innovation in the early stages of drug development.- Flcube.com
-
Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease
•
The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese pharmaceutical company, registration authorization for a subcutaneous formulation of its alpha4beta7 integrin antagonist Entyvio (vedolizumab). This new formulation is intended for use as a maintenance therapy in patients with moderately to severely active…
-
Takeda’s Strategic Shift: China Becomes Integral to Global R&D Pipeline
•
Japan’s Takeda Pharmaceuticals (NYSE: TAK) has underscored its commitment to the Chinese market at this week’s Takeda R&D China Innovation Forum 2024 in Shanghai. The forum highlighted the integration of China into the company’s global research pipeline, with President Andy Plump announcing that Chinese sites are now participating in 100%…
-
US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment
•
The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and its partner Takeda (NYSE: TAK, TYO: 4502) for their oral tyrosine kinase inhibitor Fruzaqla (fruquintinib), marking the second approval this year for a China-developed innovative drug. The drug is indicated for adult patients with previously…
-
Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919
•
US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial report that, in mutual agreement with development partner Takeda Pharmaceutical Co., Ltd (NYSE: TAK), the decision has been made to cease development of the Alzheimer’s drug candidate TAK-920/DNL919. This strategic decision was influenced by data…
